CBD for Drug-Resistant Epilepsy

When Nothing Else Works

The story of pharmaceutical-grade CBD and what it means for children and adults with treatment-resistant epilepsy.

In 2018, something happened that almost never happens in medicine. A plant-derived compound — one that had been dismissed, debated, and stigmatized for decades — was approved by the FDA as a legitimate pharmaceutical drug for one of the most devastating conditions in neurology.

That drug is Epidiolex. Its active ingredient is cannabidiol — CBD.

For the families of children with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, two catastrophic forms of childhood epilepsy, it wasn’t a wellness trend. It was, for many, the first real seizure control they had seen in years.

What is Epidiolex, and what does it treat?

Epidiolex is a pharmaceutical-grade oral CBD solution — highly purified, precisely dosed, and FDA-approved. It is the first and only plant-derived antiepileptic drug approved by the FDA.

It is approved to treat seizures associated with:

• Lennox-Gastaut syndrome (LGS) — a severe childhood epilepsy with multiple seizure types and developmental delay
• Dravet syndrome — a rare, treatment-resistant epilepsy beginning in infancy, often triggered by fever
• Tuberous sclerosis complex (TSC) — a genetic disorder causing non-cancerous tumors and epilepsy

These are not mild conditions. Most patients with these diagnoses have already tried multiple antiepileptic drugs (AEDs) and still have frequent, debilitating seizures.

What does the research show?

The clinical evidence for Epidiolex is among the strongest that exists for any CBD application — because it went through the full FDA approval process, including large, rigorous, placebo-controlled Phase 3 clinical trials.

Key findings from the trials:

• In LGS trials, Epidiolex reduced convulsive seizure frequency by approximately 37 to 44% compared to placebo.
• In Dravet syndrome trials, patients taking Epidiolex experienced a median reduction in convulsive seizures of about 39% compared to placebo.
• In TSC trials, Epidiolex significantly reduced total seizure count versus placebo.
• A meaningful proportion of patients achieved 50% or greater seizure reduction — considered clinically significant in epilepsy treatment.
• In real-world use, some patients have maintained seizure reduction for years, with ongoing studies now tracking long-term outcomes.

Recent work presented at ERN EpiCARE also highlighted Epidiolex’s effects on non-seizure outcomes in adults with developmental and epileptic encephalopathies — including improvements in alertness, sleep, and behavior.

Why does this matter beyond epilepsy?

The approval of Epidiolex did something important for the entire CBD field: it proved, definitively, that a cannabidiol product can clear the highest scientific and regulatory bar in medicine.

This matters because:

• It established that CBD has real, measurable, reproducible therapeutic effects — not just anecdote
• It created a pharmacological model — we now have dosing, pharmacokinetics, safety, and drug interaction data from rigorous trials
• It opened the door for CBD research into other conditions, because regulators and researchers can no longer dismiss the compound wholesale

The gap between pharmaceutical Epidiolex and over-the-counter CBD supplements is significant. Epidiolex is a prescription drug with precise dosing, quality controls, and clinical indications. OTC CBD supplements vary enormously in quality and concentration. But they share the same core molecule — and the science underpinning one has direct implications for how we think about the other.

What this means for you

If you or someone you love has treatment-resistant epilepsy:

• Talk to a neurologist about whether Epidiolex is an appropriate option. It requires a prescription and is typically considered after other AEDs have been tried.
• Insurance coverage varies. Epidiolex is expensive, but most major insurers cover it for FDA-approved indications. Patient assistance programs are available through the manufacturer (Jazz Pharmaceuticals).
• It does not get you high. Epidiolex contains no THC and produces no psychoactive effects.

If you use CBD supplements for other reasons and want to understand how they relate to this research:

• The FDA approval of Epidiolex is the strongest evidence we have that CBD works for at least one specific medical purpose.
• It reinforces the importance of product quality — because in the clinical trials, the CBD was pure, accurately dosed, and consistently manufactured. OTC products should be held to the highest standard you can access: third-party testing, clear CBD content, reputable manufacturers.

---

About the Original Study

Title: Epidiolex (Cannabidiol Oral Solution) — overview of clinical trials, approval, and real-world evidence for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

Year: 2025 (ongoing real-world evidence and registry data)

Key references:

• Jazz Pharmaceuticals — Epidiolex prescribing information and clinical data
• FDA approval announcement and drug label (NDA 210365)
• PubMed — Epidiolex clinical trials overview

Key researchers:

• Orrin Devinsky, MD — Professor of Neurology, NYU Langone Health. Lead investigator on the pivotal Epidiolex Phase 3 trials for Dravet syndrome and LGS. One of the world’s foremost epilepsy researchers.
• Elizabeth Thiele, MD, PhD — Director, Pediatric Epilepsy Program, Massachusetts General Hospital. Principal investigator on Epidiolex TSC trials and long-term outcomes research.

---